COSMO PHARMACEUTICALS NV (C43.DE) Stock Earnings & Estimates
Europe - FRA:C43 - NL0011832936 - Common Stock
48.8 EUR
-1.2 (-2.4%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 102.089M 56.88% | 92.78M -9.12% | 266.788M 187.55% | 218.51M -18.10% | 175.57M -19.65% | 142.8M -18.66% | 557.8M 290.62% | 753.02M 35.00% | 619.84M -17.69% | 498.68M -19.55% | 422.57M -15.26% | |
| EBITDA YoY % growth | 41.913M 126.92% | 9.974M -76.20% | 161.167M 1,515.87% | 108.5M -32.68% | 67.739M -37.57% | 100.98M 49.07% | 423.57M 319.46% | 573.78M 35.46% | 444.6M -22.51% | 339.46M -23.65% | 270.37M -20.35% | |
| EBIT YoY % growth | 28.057M 152.74% | -1.875M -106.68% | 148.882M 8,040.37% | 133.22M -10.52% | 43.649M -67.24% | 55.08M 26.19% | 381.56M 592.74% | 557.76M 46.18% | 428.58M -23.16% | 322.44M -24.77% | 253.34M -21.43% | |
| Operating Margin | 27.48% | -2.02% | 55.81% | 60.97% | 24.86% | 38.57% | 68.40% | 74.07% | 69.14% | 64.66% | 59.95% | |
| EPS YoY % growth | 1.05 29.36% | N/A 322.00% | N/A 78.51% | 6.03 -23.67% | 2.07 -65.73% | 2.99 44.57% | 19.21 542.74% | 28.25 47.06% | 21.93 -22.37% | 17.56 -19.91% | 15.17 -13.63% |
All data in EUR
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in EUR
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2024 Q2Q % growth | 177.08% | 2.71 | % | |
| Q2 2024 Q2Q % growth | 4.72 5,028.26% | 4.35 | 0.37 | 8.58% |
| Q4 2023 Q2Q % growth | 70.89% | 0.98 | % | |
| Q2 2023 Q2Q % growth | 0.09 -80.67% | 0.06 | 0.03 | 50.33% |
| Q4 2022 Q2Q % growth | 0.57 -29.78% | 0.91 | -0.33 | -36.88% |
| Q2 2022 Q2Q % growth | 0.48 219.00% | -0.06 | 0.54 | 877.78% |
| Q4 2021 Q2Q % growth | 342.86% | 0.82 | % | |
| Q2 2021 Q2Q % growth | -0.40 -90.48% | -0.41 | 0.01 | 1.96% |
| Q4 2020 Q2Q % growth | -0.34 -28.24% | -0.71 | 0.38 | 52.94% |
| Q2 2020 Q2Q % growth | -0.21 85.07% | -0.20 | -0.01 | -2.94% |
| Q4 2019 Q2Q % growth | -0.26 | -0.43 | 0.17 | 38.84% |
| Q2 2019 Q2Q % growth | -1.41 | -1.12 | -0.28 | -25.40% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2024 Q2Q % growth | 130.551M 165.79% | 123.42M | 7.131M | 5.78% |
| Q2 2024 Q2Q % growth | 136.237M 212.03% | 145.86M | -9.623M | -6.60% |
| Q4 2023 Q2Q % growth | 49.119M -18.92% | 69.36M | -20.241M | -29.18% |
| Q2 2023 Q2Q % growth | 43.661M 5.18% | 45.9M | -2.239M | -4.88% |
| Q4 2022 Q2Q % growth | 60.578M 65.27% | 59.16M | 1.418M | 2.40% |
| Q2 2022 Q2Q % growth | 41.511M 46.06% | 39.78M | 1.731M | 4.35% |
| Q4 2021 Q2Q % growth | 36.654M 4.53% | 33.66M | 2.994M | 8.89% |
| Q2 2021 Q2Q % growth | 28.42M 9.80% | 29.58M | -1.16M | -3.92% |
| Q4 2020 Q2Q % growth | 35.066M -14.45% | 27.405M | 7.661M | 27.95% |
| Q2 2020 Q2Q % growth | 25.883M 20.35% | 25.5M | 383K | 1.50% |
| Q4 2019 Q2Q % growth | 40.988M | 23.46M | 17.528M | 74.71% |
| Q2 2019 Q2Q % growth | 21.507M | 27.54M | -6.033M | -21.91% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | 0% | 2.22% |
| Revenue | N/A | N/A | -13.87% | -12.84% |